Piper Sandler has reiterated its confidence in medical device company Edwards Lifesciences (EW), with analyst Adam Maeder raising the stock's price target. The target was adjusted from $98.00 to $100.00, while the firm reaffirmed its 'Overweight' rating for the shares. This positive revision reflects continued confidence in the company's operational and financial performance. The move aligns with several other analysts who have also raised their price targets for EW. The average target price for the stock currently stands at $96.09 among 31 analysts, indicating a broad positive outlook. This upgrade is expected to bolster investor confidence in the company's growth prospects.
Get AI-powered deep analysis for every story with a paid subscription
Upgrade for Analysis